Work from the Leeper laboratory has demonstrated that anti-CD47 (pro-efferocytic therapy), delivered systemically (119, 120) or in a macrophage-specific nanotube therapy (121), holds promise in animal models of atherosclerosis, while human data has suggested anti-CD47 therapy reduces carotid artery inflammation (122). The gene discussed is CD47; the disease is atherosclerosis.